Korsana Biosciences Appoints Mark Vignola, Ph.D., as Chief Financial Officer

Proven leader with over 15 years of experience successfully implementing financial and operational strategies across biotech industry WALTHAM, Mass.–(BUSINESS WIRE)–Korsana Biosciences, Inc. (“Korsana” or the “Company”), a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced that Mark Vignola, Ph.D., has joined as Chief Financial Officer (CFO). Dr. … [Read more…]

AHF Urges EU to Stop Blocking Health Equity

BRUSSELS–(BUSINESS WIRE)–#EUStopBlockingHealthEquity–AIDS Healthcare Foundation (AHF) Europe will hold an advocacy action in Brussels on March 18 at 11:00 a.m. CET on Archimedes Street, followed by an in-person and virtual press conference at Press Club Brussels Europe titled “EU: Stop Blocking Health Equity,” urging European Commission (EC) decision-makers to support a legally binding Pathogen Access and … [Read more…]

Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide

Samsung Bioepis to receive exclusive license to develop and commercialize two novel assets including long-acting semaglutide using G2GBIO’s proprietary microsphere technology Epis NexLab, a sister company to Samsung Bioepis under Samsung Epis Holdings, also signs the agreement to collaborate in the development of the long-acting microsphere drug delivery platform INCHEON, Korea–(BUSINESS WIRE)–#Biosimilar–Samsung Bioepis Co., Ltd. … [Read more…]

YolTech Therapeutics Receives FDA Clearance to Initiate Phase 2/3 Study of In Vivo Gene-Editing Therapy YOLT-202 in Alpha-1 Antitrypsin Deficiency (AATD)

SHANGHAI–(BUSINESS WIRE)–YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for YOLT-202, the company’s investigational in vivo base-editing therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The FDA approval enables the initiation of … [Read more…]

Advanced eClinical Training Expands Nationwide Clinical Partner Network, Strengthening Medical Assistant Workforce Pipeline

NEW YORK–(BUSINESS WIRE)–Advanced eClinical Training (ACT), a national healthcare workforce training provider, today announced the continued expansion of its nationwide clinical partner network, now spanning more than 1,000 healthcare sites across the United States. The growing network supports externship placements for students enrolled in ACT’s online medical assistant training and allied health programs. The expansion … [Read more…]

Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026

Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET VANCOUVER, British Columbia & DALLAS–(BUSINESS WIRE)–Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, … [Read more…]

ACCESS GPO Announces Preferred Strategic Commercial Agreement to Provide Affera™ Mapping and Ablation System with Sphere-9™ Catheter to Ambulatory Surgery Centers

Agreement will expand access to next-generation technology for cardiac electrophysiology procedures NEW YORK–(BUSINESS WIRE)–ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter in ambulatory surgery centers (ASCs) across the United States. The agreement is designed to help physician-led ASCs gain earlier … [Read more…]

Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–$anro #cns–Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. … [Read more…]

Afya Limited Announces Fourth Quarter and Twelve Months 2025 Financial Results

Another Year of Strong Performance Guidance Achievement BELO HORIZONTE, Brazil–(BUSINESS WIRE)–Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the fourth quarter and full-year period ended December 31, 2025. Financial results are expressed in … [Read more…]

AIDS Groups Protest City-Planned Cuts to HIV/AIDS Care in Chicago

Nonprofit organizations team together to halt cuts to HIV primary care by the Department of Health; AHF, South Side Help Center, and CALOR to also give testimony at HIV Planning Committee Emergency Meeting Friday, March 13, 9:30 am – 11:30 a.m. CHICAGO–(BUSINESS WIRE)–AIDS Healthcare Foundation (AHF) and its Chicago area affiliate organizations the South Side … [Read more…]